Empagliflozin advancing on all fronts: Readying for the future with EMPEROR
11 Aug 2020;
In this final issue of our series, join us as we
look into the upcoming results of the pivotal EMPEROR trials, which will
investigate the use of empagliflozin in patients with either preserved or
reduced ejection fraction heart failure, with or without type 2 diabetes.
Understand why heart failure has such a high clinical burden, and the great
unmet need in providing solutions for it.
Contents : Per 100 u/mL + 50 mcg/mL soln for inj (10-40 pen) Insulin glargine 3.64 mg (equiv to 100 u), lixisenatide 50 mcg. Per 100 u/mL + 33 mcg/mL soln for inj (30-60 pen) Insulin glargine 3.64 mg (equiv to 100 u), lixisenatide 33 mcg
Indications/Uses : In combination w/ metformin for adults w/ type 2 DM to improve glycaemic control when metformin alone, or metformin combined w/ another oral glucose lowering drugs, or w/ basal insulin does not provide adequate glycaemic control.
Indications/Uses : Amebiasis; urogenital trichomoniasis; non-specific vaginitis; giardiasis. Curative treatment of medico-surgical infections due to susceptible anaerobic pathogens. Prophylaxis against infections caused by susceptible anaerobic pathogens in high risk surgical contexts. Conversion from prophylactic or curative injectable treatment of infections due to susceptible anaerobic pathogens.
Indications/Uses : Treatment of community-acquired pneumonia, UTI including complicated UTI, skin & soft tissue infections. Tab: Treatment of adults >18 yr w/ mild, moderate & severe infections caused by susceptible strains of microorganisms in the following diseases: Nosocomial pneumonia, acute bacterial exacerbation of chronic bronchitis, acute maxillary sinusitis, chronic bacterial prostatitis; mild to moderate uncomplicated skin & skin structure infections, acute pyelonephritis & uncomplicated UTI.
Indications/Uses : Control of serum phosphorus (P) in patients w/ chronic kidney disease (CKD) on dialysis; hyperphosphatemia in adults receiving hemo- or peritoneal dialysis. Adult CKD patients not on dialysis w/ serum P >1.78 mmol/L (5.5 mg/dL). Control of serum P in ped patients (>6 yr & BSA of >0.75 m2) w/ CKD.
Indications/Uses : Induction & augmentation of labor, to control postpartum bleeding & uterine hypotonicity in 3rd stage of labor. Promote lactation in cases of faulty milk ejection.
Sign Out
_400pxW.png)
